Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 1;37(7-8):303–320. doi: 10.1101/gad.350078.122

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Zacarías-Fluck et al.; Published by Cold Spring Harbor Laboratory Press

This article, published in Genes & Development, is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Figure 6. — Melanoma patients stratified by a six-gene signature show improved OS with lower metastatic capacity and increased immune response. (A) Survival of melanoma patients discriminated by a six-gene signature. (B) Patients with good prognosis have a lower hypoxia index and a lower fraction of the genome altered. (C) Volcano plot depicting gene expression of good prognosis versus poor prognosis patients. (D) Overlap between Omomyc-modulated genes in preclinical settings (percentage shown) and genes significantly enriched in good and poor prognosis patients. Preranked GSEA shows decreased MYC transcriptional activity, metastatic capacity, and melanoma relapse (E) and decreased expression of EMT genes, E2F targets, and cell cycle genes (F). (G) Tumors from patients with good prognosis show enrichment of genes related to immune response. (H) There was no evidence of differential MYC transcriptional repression activity in either group of patients.